Envelope-chimeric entry-targeted measles virus escapes neutralization and achieves oncolysis

Molecular Therapy

Volumn 19, Issue 10, 2011, Pages 1813-1820

  Miest, Tanner S ^a   Yaiw, Koon Chu ^a,b   Frenzke, Marie ^a   Lampe, Johanna ^a,c   Hudacek, Andrew W ^a   Springfeld, Christoph ^a,d   Von Messling, Veronika ^a,e   Ungerechts, Guy ^a,f   Cattaneo, Roberto ^a  

^a MAYO GRADUATE SCHOOL   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e INRS INSTITUT ARMAND FRAPPIER   (Canada)

^f GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC PROTEIN; FLUDARABINE; MEASLES ANTIBODY; ONCOLYTIC VIRUS; PURINE NUCLEOSIDE PHOSPHORYLASE; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANINE DISTEMPER MORBILLIVIRUS; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; HUMAN; IMMUNIZATION; IMMUNOCOMPETENCE; MEASLES; MEASLES VIRUS; MOUSE; NONHUMAN; ONCOLOGY; ONCOLYTIC VIROTHERAPY; PROTEIN EXPRESSION; PROTEIN FUNCTION; SYSTEMIC THERAPY; TUMOR CELL; VIRUS NEUTRALIZATION; VIRUS TITRATION;

CANINE DISTEMPER VIRUS; MEASLES VIRUS; MURINAE; MUS;

EID: 80053571003     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2011.92     Document Type: Article

References (50)

1. Liu, TC, Galanis, E and Kirn, D (2007). Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Pract Oncol 4: 101-117. (Pubitemid 46189539)
2. Kumar, S, Gao, L, Yeagy, B and Reid, T (2008). Virus combinations and chemotherapy for the treatment of human cancers. Curr Opin Mol Ther 10: 371-379.
3. Ottolino-Perry, K, Diallo, JS, Lichty, BD, Bell, JC and McCart, JA (2010). Intelligent design: combination therapy with oncolytic viruses. Mol Ther 18: 251-263.
4. Cattaneo, R, Miest, T, Shashkova, EV and Barry, MA (2008). Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat Rev Microbiol 6: 529-540. (Pubitemid 351850977)
5. Russell, SJ and Peng, KW (2009). Measles virus for cancer therapy. Curr Top Microbiol Immunol 330: 213-241.
6. del Valle, JR, Devaux, P, Hodge, G, Wegner, NJ, McChesney, MB and Cattaneo, R (2007). A vectored measles virus induces hepatitis B surface antigen antibodies while protecting macaques against measles virus challenge. J Virol 81: 10597-10605. (Pubitemid 47463333)
7. Billeter, MA, Naim, HY and Udem, SA (2009). Reverse genetics of measles virus and resulting multivalent recombinant vaccines: applications of recombinant measles viruses. Curr Top Microbiol Immunol 329: 129-162.
8. Brandler, S, Ruffie, C, Najburg, V, Frenkiel, MP, Bedouelle, H, Desprès, P et al. (2010). Pediatric measles vaccine expressing a dengue tetravalent antigen elicits neutralizing antibodies against all four dengue viruses. Vaccine 28: 6730-6739.
9. Hammond, AL, Plemper, RK, Zhang, J, Schneider, U, Russell, SJ and Cattaneo, R (2001). Single-chain antibody displayed on a recombinant measles virus confers entry through the tumor-associated carcinoembryonic antigen. J Virol 75: 2087-2096. (Pubitemid 32147548)
10. Nakamura, T, Peng, KW, Harvey, M, Greiner, S, Lorimer, IA, James, CD et al. (2005). Rescue and propagation of fully retargeted oncolytic measles viruses. Nat Biotechnol 23: 209-214. (Pubitemid 40255331)
11. Ungerechts, G, Springfeld, C, Frenzke, ME, Lampe, J, Johnston, PB, Parker, WB et al. (2007). Lymphoma chemovirotherapy: CD20-targeted and convertase-armed measles virus can synergize with fludarabine. Cancer Res 67: 10939-10947. (Pubitemid 350145923)
12. Ungerechts, G, Springfeld, C, Frenzke, ME, Lampe, J, Parker, WB, Sorscher, EJ et al. (2007). An immunocompetent murine model for oncolysis with an armed and targeted measles virus. Mol Ther 15: 1991-1997. (Pubitemid 350011739)
13. Msaouel, P, Dispenzieri, A and Galanis, E (2009). Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview. Curr Opin Mol Ther 11: 43-53.
14. Galanis, E, Hartmann, LC, Cliby, WA, Long, HJ, Peethambaram, PP, Barrette, BA et al. (2010). Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res 70: 875-882.
15. Robbins, PF, Kantor, JA, Salgaller, M, Hand, PH, Fernsten, PD and Schlom, J (1991). Transduction and expression of the human carcinoembryonic antigen gene in a murine colon carcinoma cell line. Cancer Res 51: 3657-3662.
16. Williams, SR, Goddard, JM and Martin, DW Jr (1984). Human purine nucleoside phosphorylase cDNA sequence and genomic clone characterization. Nucleic Acids Res 12: 5779-5787.
17. Radecke, F, Spielhofer, P, Schneider, H, Kaelin, K, Huber, M, Dötsch, C et al. (1995). Rescue of measles viruses from cloned DNA. EMBO J 14: 5773-5784.
18. Parker, WB, Allan, PW, Shaddix, SC, Rose, LM, Speegle, HF, Gillespie, GY et al. (1998). Metabolism and metabolic actions of 6-methylpurine and 2-fluoroadenine in human cells. Biochem Pharmacol 55: 1673-1681. (Pubitemid 28223460)
19. Ungerechts, G, Frenzke, ME, Yaiw, KC, Miest, T, Johnston, PB and Cattaneo, R (2010). Mantle cell lymphoma salvage regimen: synergy between a reprogrammed oncolytic virus and two chemotherapeutics. Gene Ther 17: 1506-1516.
20. Rose, NF, Marx, PA, Luckay, A, Nixon, DF, Moretto, WJ, Donahoe, SM et al. (2001). An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 106: 539-549. (Pubitemid 32879316)
21. Roberts, DM, Nanda, A, Havenga, MJ, Abbink, P, Lynch, DM, Ewald, BA et al. (2006). Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 441: 239-243.
22. Gallione, CJ and Rose, JK (1983). Nucleotide sequence of a cDNA clone encoding the entire glycoprotein from the New Jersey serotype of vesicular stomatitis virus. J Virol 46: 162-169. (Pubitemid 13161255)
23. von Messling, V, Zimmer, G, Herrler, G, Haas, L and Cattaneo, R (2001). The hemagglutinin of canine distemper virus determines tropism and cytopathogenicity. J Virol 75: 6418-6427. (Pubitemid 32578161)
24. Tao, T, Durbin, AP, Whitehead, SS, Davoodi, F, Collins, PL and Murphy, BR (1998). Recovery of a fully viable chimeric human parainfluenza virus (PIV) type 3 in which the hemagglutinin-neuraminidase and fusion glycoproteins have been replaced by those of PIV type 1. J Virol 72: 2955-2961. (Pubitemid 28175533)
25. Tao, T, Skiadopoulos, MH, Davoodi, F, Riggs, JM, Collins, PL and Murphy, BR (2000). Replacement of the ectodomains of the hemagglutinin-neuraminidase and fusion glycoproteins of recombinant parainfluenza virus type 3 (PIV3) with their counterparts from PIV2 yields attenuated PIV2 vaccine candidates. J Virol 74: 6448-6458. (Pubitemid 30429812)
26. Bucheit, AD, Kumar, S, Grote, DM, Lin, Y, von Messling, V, Cattaneo, RB et al. (2003). An oncolytic measles virus engineered to enter cells through the CD20 antigen. Mol Ther 7: 62-72. (Pubitemid 36305359)
27. Schneider, U, Bullough, F, Vongpunsawad, S, Russell, SJ and Cattaneo, R (2000). Recombinant measles viruses efficiently entering cells through targeted receptors. J Virol 74: 9928-9936.
28. Springfeld, C, von Messling, V, Tidona, CA, Darai, G and Cattaneo, R (2005). Envelope targeting: hemagglutinin attachment specificity rather than fusion protein cleavage-activation restricts Tupaia paramyxovirus tropism. J Virol 79: 10155-10163. (Pubitemid 41098556)
29. Funke, S, Maisner, A, Mühlebach, MD, Koehl, U, Grez, M, Cattaneo, R et al. (2008). Targeted cell entry of lentiviral vectors. Mol Ther 16: 1427-1436.
30. Funke, S, Schneider, IC, Glaser, S, Mühlebach, MD, Moritz, T, Cattaneo, R et al. (2009). Pseudotyping lentiviral vectors with the wild-type measles virus glycoproteins improves titer and selectivity. Gene Ther 16: 700-705.
31. Anliker, B, Abel, T, Kneissl, S, Hlavaty, J, Caputi, A, Brynza, J et al. (2010). Specific gene transfer to neurons, endothelial cells and hematopoietic progenitors with lentiviral vectors. Nat Methods 7: 929-935.
32. Parks, R, Evelegh, C and Graham, F (1999). Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration. Gene Ther 6: 1565-1573. (Pubitemid 29465515)
33. Lorin, C, Mollet, L, Delebecque, F, Combredet, C, Hurtrel, B, Charneau, P et al. (2004). A single injection of recombinant measles virus vaccines expressing human immunodeficiency virus (HIV) type 1 clade B envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV. J Virol 78: 146-157. (Pubitemid 37549727)
34. Graves, M, Griffin, DE, Johnson, RT, Hirsch, RL, de Soriano, IL, Roedenbeck, S et al. (1984). Development of antibody to measles virus polypeptides during complicated and uncomplicated measles virus infections. J Virol 49: 409-412. (Pubitemid 14221312)
35. Marie, JC, Saltel, F, Escola, JM, Jurdic, P, Wild, TF and Horvat, B (2004). Cell surface delivery of the measles virus nucleoprotein: a viral strategy to induce immunosuppression. J Virol 78: 11952-11961. (Pubitemid 39390780)
36. Bankamp, B, Brinckmann, UG, Reich, A, Niewiesk, S, ter Meulen, V and Liebert, UG (1991). Measles virus nucleocapsid protein protects rats from encephalitis. J Virol 65: 1695-1700.
37. Wild, TF, Bernard, A, Spehner, D and Drillien, R (1992). Construction of vaccinia virus recombinants expressing several measles virus proteins and analysis of their efficacy in vaccination of mice. J Gen Virol 73 (Pt 2): 359-367.
38. Schlereth, B, Germann, PG, ter Meulen, V and Niewiesk, S (2000). DNA vaccination with both the haemagglutinin and fusion proteins but not the nucleocapsid protein protects against experimental measles virus infection. J Gen Virol 81(Pt 5): 1321-1325. (Pubitemid 30232718)
39. Munguia, A, Ota, T, Miest, T and Russell, SJ (2008). Cell carriers to deliver oncolytic viruses to sites of myeloma tumor growth. Gene Ther 15: 797-806. (Pubitemid 351627364)
40. Mader, EK, Maeyama, Y, Lin, Y, Butler, GW, Russell, HM, Galanis, E et al. (2009). Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model. Clin Cancer Res 15: 7246-7255.
41. Liu, C, Russell, SJ and Peng, KW (2010). Systemic therapy of disseminated myeloma in passively immunized mice using measles virus-infected cell carriers. Mol Ther 18: 1155-1164.
42. Myers, RM, Greiner, SM, Harvey, ME, Griesmann, G, Kuffel, MJ, Buhrow, SA et al. (2007). Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide. Clin Pharmacol Ther 82: 700-710. (Pubitemid 350114828)
43. von Messling, V and Cattaneo, R (2002). Amino-terminal precursor sequence modulates canine distemper virus fusion protein function. J Virol 76: 4172-4180. (Pubitemid 34309552)
44. Sidhu, MS, Husar, W, Cook, SD, Dowling, PC and Udem, SA (1993). Canine distemper terminal and intergenic non-protein coding nucleotide sequences: completion of the entire CDV genome sequence. Virology 193: 66-72.
45. Singh, M, Cattaneo, R and Billeter, MA (1999). A recombinant measles virus expressing hepatitis B virus surface antigen induces humoral immune responses in genetically modified mice. J Virol 73: 4823-4828. (Pubitemid 29246742)
46. Spearman, C (1908). The method of right and wrong cases (constant stimuli) without Gauss's formulae. Br J Psychol 2: 227-242.
47. Kärber, G (1931). Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Arch Exp Pathol Pharmakol 162: 480-483.
48. Toth, AM, Devaux, P, Cattaneo, R and Samuel, CE (2009). Protein kinase PKR mediates the apoptosis induction and growth restriction phenotypes of C protein-deficient measles virus. J Virol 83: 961-968.
49. Cathomen, T, Naim, HY and Cattaneo, R (1998). Measles viruses with altered envelope protein cytoplasmic tails gain cell fusion competence. J Virol 72: 1224-1234. (Pubitemid 28116907)
50. Zhu, YD, Heath, J, Collins, J, Greene, T, Antipa, L, Rota, P et al. (1997). Experimental measles. II. Infection and immunity in the rhesus macaque. Virology 233: 85-92. (Pubitemid 27348770)